Qiong Zhang

Dr. Qiong Zhang


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 September 2024 in Biomedicines
Verified
Journal Article
Open access
PDF file
BLBingyu Li
Bingyu Li
QZQiong Zhang
Qiong Zhang
CCClaire Castaneda
Claire Castaneda
SCShelly M Cook
Shelly M Cook
Pancreatic ductal adenocarcinoma (PDAC), a leading cause of cancer mortality in the United States, presents significant treatment challenges due to its late diagnosis and poor prognosis. Despite advances, the five-year survival rates remain dismally low, with only a fraction of patients eligible for potentially curative surgical interventions. This review aims to comprehensively examine the current landscape of targeted therapies in PDAC, focusing on recent developments in precision medicine approaches. We explore various molecular targets, including KRAS mutations, DNA damage repair deficiencies, mismatch repair pathway alterations, and rare genetic fusions. The review discusses emerging therapies, such as PARP inhibitors, immune checkpoint inhibitors, and novel targeted agents, like RET and NTRK inhibitors. We analyze the results of key clinical trials and highlight the potential of these targeted approaches in specific patient subgroups. Recent developments in PDAC research have emphasized precision oncology, facilitated by next-generation sequencing and the identification of genetic and epigenetic alterations. This approach tailors treatments to individual genetic profiles, improving outcomes and reducing side effects. Significant strides have been made in classifying PDAC into various subtypes, enhancing therapeutic precision. The identification of specific mutations in genes like KRAS, along with advancements in targeted therapies, including small molecule inhibitors, offers new hope. Furthermore, emerging therapies targeting DNA repair pathways and immunotherapeutic strategies also show promising results. As research evolves, integrating these targeted therapies with conventional treatments might improve survival rates and quality of life for PDAC patients, underscoring the shift towards a more personalized treatment paradigm.

Verified
Journal Article
Open access
PDF file
YLYan Li
Yan Li
QZQiong Zhang
Qiong Zhang
SCShelly M Cook
Shelly M Cook
Colorectal cancer (CRC) is the third most common cancer and a leading cause of cancer-related mortality worldwide, with prognosis significantly deteriorating at advanced stages. While current diagnostic methods, such as colonoscopy and tissue biopsy, are widely employed in clinical practice, they are invasive, expensive, and limited in assessing tumor heterogeneity and monitoring disease processes, including therapy response. Therefore, early and accurate detection, coupled with minimal invasion and cost-effective strategies, are critical for improving patient outcomes. Liquid biopsy has emerged as a promising, minimally invasive alternative, enabling the detection of tumor-derived components. This approach is increasingly utilized in clinical settings. The current key liquid biopsy modalities in CRC include circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and RNA-based biomarkers such as long non-coding RNAs (lncRNAs), microRNAs(miRNAs), and circular RNAs (circRNAs), and tumor-educated platelets (TEPs). These methods provide valuable insights into genetic and epigenetic tumor alterations, and serve as indicators for early detection, treatment monitoring, and recurrence prediction. However, challenges such as assay standardization and variability in sensitivity persist. This review delves into the clinical applications of liquid biopsy in CRC management, highlighting the transformative roles of ctDNA, CTCs, and non-coding RNAs, TEPs in early detection, prognostic assessment, and personalized therapy. In addition, it addresses current limitations and explores potential advancements to facilitate their integration into routine clinical practice.

7 October 2025 in Academic Pathology
Verified
Journal Article
Open access
ATAlex P. Tannenbaum
Alex P. Tannenbaum
PWPaul S. Weisman
Paul S. Weisman
JGJessica Gulliver
Jessica Gulliver
RSRyan Sappenfield
Ryan Sappenfield
QZQiong Zhang
Qiong Zhang
EBErin G. Brooks
Erin G. Brooks
With the modern paradigm shift toward an integrated, organ-systems-based structure, United States medical students now receive limited formal training in histology. This places additional strain on pathology departments and assigned-resident educators during medical student clinical clerkships, as they must focus more time on basic principles of histology instead of the cases at hand. Schools have explored the use of asynchronous modular learning resources to build and support histology education outside of the traditional didactic settings, but the successful integration of modular content with traditional pathology rotations has not yet been fully explored. This survey-based study aims to evaluate the effectiveness of a newly implemented anatomic pathology curriculum that integrates asynchronous modular histology content, created in-house by department residents and faculty, with service-based pathology rotations. Postrotation surveys of medical student learners (n = 31/35, 89%), using a 10-point Likert scale, gathered across the 2024–2025 academic year, revealed high ratings for rotation organization, usefulness, histology education, module experience, and rotation personalization. Free-response feedback themes from learners reinforced the value of the integrated educational experience and helpfulness of the modular content. Postrotation surveys of residents assigned to these students (n = 7/14, 50%) revealed a better balance between management of daily workloads and the educational experience of their learners. Faculty surveys (n = 10) revealed a high perceived usefulness of the new curricular model. In all, implementation of this novel curriculum has been effective and popular with rotating students, residents, and faculty at our institution and could likewise serve as an effective model for others.

25 November 2024 in Pediatric and Developmental Pathology
Verified
Journal Article
Closed access
QZQiong Zhang
Qiong Zhang
AAAaron Axelbaum
Aaron Axelbaum
KFKatryn Furuya
Katryn Furuya
JGJessica Gulliver
Jessica Gulliver
Translocations within the TFE gene resulting in oncogenic fusion proteins have been associated with multiple neoplasms. De novo mutations in the X-linked gene TFE3 in exons 3 and 4 are considered to contribute to lysosomal storage disorder-like features. However, the histologic findings within the livers of patients with TFE3 mutations are not well characterized. The authors report a case of a 12 day old term male who was admitted to the pediatric intensive care unit and went on to develop worsening direct hyperbilirubinemia and hepatomegaly. Due to the constellation of clinical findings, whole genome sequencing was performed and a rare de novo hemizygous mutation was identified in the TFE3 gene (c.560C > T; p.Thr187Met) which was thought to be likely pathogenic. The patient subsequently had 2 liver biopsies performed, both with similar histologic findings. The liver was found to have a giant cell hepatitis pattern of injury with severe cholestasis and extensive pseudorosette formation. Additional studies are needed to understand the histologic changes which could be associated with mutations in the TFE3 gene. The impact of a TFE3 mutation on the liver represents an area where further study is necessary to provide prognostic and therapeutic guidance for future patients.